Search clinical trials for: Cyclosporine 0.09% Ophthalmic Solution

Total 2162 results

Hanlim Pharm. Co., Ltd.

Completed

Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group (Cyclosporine)

Dry Eye Syndromes

Korea, Republic of
Hanlim Pharm. Co., Ltd.

Completed

Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease (HL_TSPR_302)

Dry Eye Syndromes

Korea, Republic of
Allergan

Completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Austria
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Allergan

Completed

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Eyelash Hypotrichosis

United States
Mahidol University

Completed

Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

Thailand
Mitotech, SA
ORA, Inc.

Completed

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Keratoconjunctivitis Sicca

United States
Alcon Research

Completed

A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye

Dry Eye
Qlaris Bio, Inc.

Not yet recruiting

Qlaris Phase 2 Study in NTG Patients

Glaucoma | Normal Tension Glaucoma (NTG) | Low-Tension Glaucoma, Bilateral | Low-Tension Glaucoma, Unspecified Eye

Korea, Republic of, Philippines
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland
Allergan

Completed

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

Dry Eye Syndromes

United States
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Tulane University
Allergan

Completed

Topical Bimatoprost for Chemical Blepharoplasty

Dermatochalasis

United States
Gian Sagar Medical College and Hospital

Withdrawn

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Vitiligo | Repigmentation
Allergan

Completed

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Alopecia Areata | Eyelash Hypotrichosis

United States, Brazil
Taejoon Pharmaceutical Co., Ltd.

Completed

Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients

Dry Eye | Dry Eye Syndromes

Korea, Republic of
University of Missouri-Columbia

Terminated

Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease

Dry Eye Syndromes

United States
Allergan

Completed

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Hypotrichosis

United States
Alcon Research

Completed

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Ocular Hypertension | Glaucoma
Allergan

Completed

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Open-Angle Glaucoma

Belgium
Peking University Third Hospital

Recruiting

The Effect of 0.05% CsA Eye Drops on Post-refractive Surgery Dry Eye

Dry Eye

China
Campus Bio-Medico University

Completed

Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery (CSA2020)

Ocular Inflammation | Ocular Surface Disease

Italy
Taejoon Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes

Dry Eye Syndromes

Korea, Republic of
Surface Pharmaceuticals, Inc.

Completed

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Alcon Research

Completed

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Ocular Hypertension | Glaucoma | Open-Angle Glaucoma
M.D. Anderson Cancer Center
Allergan

Withdrawn

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

Epiphora
Aerie Pharmaceuticals

Completed

Rocklatan® Evaluation

Glaucoma

United States
University of Maryland, Baltimore
Aerie Pharmaceuticals

Completed

Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

Ocular Hypertension | Suspect Glaucoma

United States
Boston Sight

Withdrawn

Novel Use of Restasis and PROSE Devices

Ocular Surface Disease

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Allergan

Completed

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Dry Eye Disease

United States
Allergan

Completed

Study of Cyclosporine in Post-LASIK Patients

Laser In Situ Keratomileusis

United States
Farwaniya Hospital

Recruiting

Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis

Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis

Kuwait
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Allergan

Completed

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® (EMPOWER)

Dry Eye Syndromes

United States
Spherium Biomed
Hospital Infantil Universitario Niño Jesús, Madrid, Spain; Germans Trias i... and other collaborators

Completed

Topical Solution for the Treatment of Atopic Dermatitis (CYCLATOP)

Atopic Dermatitis

Spain
Allergan

Completed

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy (IMPACT)

Dry Eye Syndromes

United States
Bausch & Lomb Incorporated
Synteract, Inc.

Completed

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Keratoconjunctivitis Sicca

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Massachusetts Eye and Ear Infirmary

Terminated

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Dry Eye Syndromes

Canada
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Keratoconjunctivitis Sicca

United States
ORA, Inc.
Palatin Technologies, Inc

Completed

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

Dry Eye Disease

United States

3

Subscribe